

Exchange Act. o

Item 8.01. Other Events.

On February 5, 2018, AMAG Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved its application to broaden the existing label for Feraheme® (ferumoxytol injection) beyond the current chronic kidney disease indication to include all eligible adult iron deficiency anemia patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	<u>Press release, dated February 5, 2018</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMAG
PHARMACEUTICALS, INC.

By: /s/ Joseph D. Vittiglio
Joseph D. Vittiglio
Executive Vice President,
General Counsel, Quality &
Corporate Secretary

Date: February 5, 2018